| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Concentra Group Holdings Parent, Inc.
$33.69
-0.37 (-1.07%)
Market Cap
4.29 B
EPS
1.55
P/E Ratio
21.54 $
Value Trade
16.42 M
SEC Financials
Q2 2026Dilution Risk
Revenue
606.03 M
Total Assets
3.01 B
Total Liabilities
2.50 B
Equity
477.10 M
5.54 %
Week
6.58 %
1 Month
33.82 %
3 Month
44.58 %
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
158.04 M
Monthly Burn
-
Runway
-
Burn Trend
StableSEC Filing
Aug 6, 2026
Overview
Volume
360.83 K
52 Week Range
18.55 - 35.15
% held by Insiders
10.5 %
% held by Institutions
88.02 %
Enterprise Value
4.15 B
Total Shares
127.96 M
Short %
2.96 %
Float Shares
115.30 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CON
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CON Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-CON
Aug 10, 2026▼ -1.1%today
Concentra to Present at Upcoming Investor Conferences
Concentra Group Holdings Parent, Inc. has announced its participation in several upcoming investor conferences, including the Bank of America Virtual SMID Cap Conference and the Wells Fargo Healthcare Conference. This engagement highlights the company's position as a leading provider of occupational health services in the U.S. The conferences are scheduled for August and September 2026.
Read more →-CON
Aug 6, 2026▲ +11.5%on this news
Concentra Group Holdings Parent, Inc. Announces Results For Its Second Quarter Ended June 30, 2026 and Raises FY 2026 Guidance
Concentra Group Holdings Parent, Inc. reported strong financial results for the second quarter of 2026, highlighting a revenue increase of 10.0% and a significant net income growth of 46.5%. The company also saw a 22.5% rise in Adjusted EBITDA. Additionally, Concentra raised its full-year guidance for 2026, signaling positive expectations for the remainder of the year.
Read more →-CON
Jul 20, 2026Concentra Expands into Idaho with Opening of Boise Medical Center
Concentra has announced the opening of its first medical center in Idaho, located in Boise. This expansion aims to improve access to occupational health services for employers and employees in the region. The center is situated in Federal Way Plaza, making it easily accessible for the local workforce.
Read more →-CON
Jul 13, 2026Concentra Expands Near Kansas City International Airport with New Medical Center
Concentra has announced the opening of a new medical center in Kansas City, Missouri, aimed at enhancing access to occupational health services. This facility is strategically located near the Kansas City International Airport, catering to the needs of the local workforce. The expansion reflects Concentra's commitment to providing specialized health services in a growing business hub.
Read more →-CON
Jul 9, 2026Concentra to Announce Second Quarter 2026 Results on Thursday, August 6, 2026
Concentra Group Holdings Parent, Inc. will announce its financial results for the second quarter of 2026 on August 6, 2026. The announcement will occur after market close, followed by a conference call on August 7, 2026, at 9 a.m. ET. Stakeholders can access the call via a live webcast.
Read more →-CON
Jun 24, 2026Concentra Expands Arizona Presence with New Goodyear Medical Center
Concentra has announced the opening of a new medical center in Goodyear, Arizona. This expansion aims to enhance healthcare access in the region. The new facility will provide a range of medical services to the local community.
Read more →-CON
May 7, 2026Concentra Group Holdings Parent, Inc. Announces Results for Its First Quarter Ended March 31, 2026, Cash Dividend, and Raised FY 2026 Guidance
Concentra Group Holdings Parent, Inc. announced its results for the first quarter ending March 31, 2026. However, the article provides minimal details about the financial performance or the specifics of the cash dividend and raised guidance. Overall, the lack of information limits the understanding of the company's current status.
Read more →-CON
Apr 14, 2026Concentra Chief Medical Officer Dr. Anderson to Retire After 33 Years
Dr. Anderson, the Chief Medical Officer of Concentra, has announced his retirement after 33 years of service. His departure signifies a significant transition for the company, which may encounter difficulties in leadership continuity. The impact of his retirement on Concentra's future operations remains to be seen.
Read more →-CON
Jun 2, 2025Concentra Announces Closing of Pivot Onsite Innovations Acquisition ADDISON, TEXAS - Concentra Group Holdings Parent, Inc. ("Concentra," "the Company," "we," "us," or "our") (NYSE: CON)
Concentra Group Holdings Parent, Inc. has closed the acquisition of Pivot Onsite Innovations from Athletico Physical Therapy for $55 million. This acquisition significantly enhances Concentra's onsite health segment, doubling its size and expanding its reach to approximately 350 health clinics across over 40 states. The integration aims to improve service offerings for large employers while maintaining high-quality clinical care. Key leadership from Pivot will transition to Concentra to ensure continuity and growth for the newly expanded organization.
Read more →-CON
Mar 31, 2025Concentra Announces Signing of Definitive Agreement to Acquire Pivot Onsite Innovations ADDISON, TEXAS - Concentra Group Holdings Parent, Inc. ("Concentra," "the Company," "we," "us," o
Concentra Group Holdings has signed a definitive agreement to acquire Pivot Onsite Innovations, a leader in onsite health services. This strategic move aims to enhance Concentra's service offerings, effectively doubling the capacity of its Onsite Health division. Key leaders from Pivot are set to transition into Concentra to ensure continuity. The transaction is valued at $55 million, with expectations to close in Q2 2025, subject to customary conditions.
Read more →-CON
Jan 22, 2025Concentra Announces Preliminary 2024 Financial Results, Agreement To Acquire Nova Medical Centers, and 2025 Financial Guidance ADDISON, TEXAS
Concentra has announced its preliminary financial results for 2024, along with plans to acquire Nova Medical Centers, enhancing its occupational health services. The acquisition is valued at $265 million and aims to improve access to healthcare for employers. Concentra's positive 2025 guidance reflects strong business performance from the previous year. The deal is anticipated to close in the first quarter of 2025, subject to standard regulatory approvals.
Read more →-CON
Nov 12, 2024xA9;2024 Concentra Inc. All rights reserved. Investor Presentation November 2024 ©2024 Concentra Inc. All rights reserved. Disclaimer 2 Forward-Looking Statements This presentation contains forward-looking statement
Concentra Inc. presented an overview of its recent performance and leadership structure during its November 2024 investor presentation. The company, which operates the largest network of occupational health services in the U.S., reported a modest year-to-date revenue increase. The presentation emphasized the extensive experience of its leadership team in healthcare and their commitment to improving worker health. No specific risks or negative projections were detailed in the information provided.
Read more →-CON
Oct 31, 2024Concentra Group Holdings Parent, Inc. Announces Results For Its Third Quarter Ended
Concentra Group Holdings Parent, Inc. reported positive results for its third quarter ended September 30, 2024, demonstrating a revenue increase of 3.3% compared to the prior year. The company's income from operations increased by 6.5%, reflecting solid execution and strategic progress, including successful separation from Select Medical. Additionally, Concentra declared a cash dividend of $0.0625 per share, payable on November 22, 2024. The leadership expressed confidence in achieving their business objectives and anticipates continued growth moving forward.
Read more →-CON
Aug 1, 2024Concentra Group Holdings Parent, Inc. Announces Results For Its Second Quarter Ended
Concentra Group Holdings Parent, Inc. announced its second quarter results for 2024, showing a revenue increase of 2.3% to $477.9 million despite a decrease in net income and earnings per share. The company completed a successful initial public offering, raising $528.8 million, while patient visits dropped slightly compared to the previous year. Concentra continues to expand its facilities, now operating 547 occupational health centers and 154 onsite clinics, emphasizing its commitment to improving workforce health.
Read more →Competitive Position
How CON ranks across every disease it competes inCompetitive Position is a premium feature
See how CON ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial